Trial Profile
A Multicenter, 180-day Pragmatic Clinical Trial to Measure the Difference in All-cause Hospitalizations for Patients Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary) ; Antipsychotics
- Indications Bipolar I disorders; Major depressive disorder; Schizophrenia
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 14 Nov 2018 Status changed from recruiting to discontinued.
- 29 Aug 2018 New trial record